|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 22, 2017 ) Anti-infecive drugs market covers the drugs that are used for the treatment of infectious diseases such as Zika, tuberculosis, typhoid, vaginosis, syphilis, human papillomarivus, human immunodeficiency virus/AIDS, influenza, and other infectious diseases. Some of the major drugs used for the treatment of infectious diseases are Harvoni, Sovaldi, Baxdela, Anthim (obiltoxaximab), Vaxchora, Vemlidy, Prevnar 13, and Zinplava.
For more information about this report at http://www.reportsweb.com/anti-infective-drugs-market-global-report-2017
The global anti-infective drugs market was estimated to be around $114 billion as of 2016. The anti-infective drugs market made up around 10.5% of the overall pharmaceuticals market in 2016. The anti-infective drugs market was the sixth largest market in the global pharmaceutical market in 2016.
Strategic Collaboration
Companies in this market are very active with multiple strategic collaborations and agreements. Top companies in the infectious diseases drugs market are strategically partnering and collaborating with other companies and government agencies to broaden their products, technologies and services. For instance, in January 2016, Takeda announced development of Zika vaccine with upto $312 million funding from the Biomedical Advanced Research and Development Authority (BARDA).
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001890205/sample
Product Launch
Companies in this market are working towards constant innovation in design and technology to make infectious drugs that are more efficant. In December 2015, Sanofi launched Dengvaxia in Mexico after receiving approval from Federal Commission for the Protection. Dengvaxia is used in the treatment of Dengue.
Companies Mentioned
Antibiotics, Antivirals
Antifungals, Others (Antihelmethic, Antiprotozoal)
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001890205/buying
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
